Managed entry agreements for pharmaceuticals: the European experience

[1]  A. M. Menti,et al.  The Italian Horizon Scanning Project , 2009, European Journal of Clinical Pharmacology.

[2]  C. Sudlow,et al.  Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis , 2003, BMJ : British Medical Journal.

[3]  A. Messori,et al.  A Uniform Procedure for Reimbursing the Off-Label Use of Antineoplastic Drugs According to the Value-for-Money Approach , 2011, Journal of chemotherapy.

[4]  G. Casadei,et al.  Risk sharing agreements: What lessons from Italy? , 2011, International Journal of Technology Assessment in Health Care.

[5]  Stephen Chapman,et al.  Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care , 2003, BMJ : British Medical Journal.

[6]  P. Barros.  The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry. , 2011, Health economics.

[7]  J. Collier.  The Pharmaceutical Price Regulation Scheme , 2007, BMJ : British Medical Journal.

[8]  M. Mcclellan,et al.  Satisfaction guaranteed--"payment by results" for biologic agents. , 2007, The New England journal of medicine.

[9]  Marianne Klemp,et al.  What principles should govern the use of managed entry agreements? , 2011, International Journal of Technology Assessment in Health Care.

[10]  B. O'brien,et al.  Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget. , 2005, Health economics.

[11]  J. Espín,et al.  Pharmaceutical Pricing and Reimbursement Information (PPRI) - New PPRI analysis including Spain , 2009 .

[12]  James Raftery,et al.  Multiple sclerosis risk sharing scheme: a costly failure , 2010, BMJ : British Medical Journal.

[13]  H. Kohli.  Scottish Medicines Consortium. , 2005, The National medical journal of India.

[14]  T. Walley,et al.  Risk Sharing and Payment by Results , 2008, Clinical pharmacology and therapeutics.

[15]  Adrian Towse,et al.  Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong? , 2010, British journal of clinical pharmacology.

[16]  Ken Paterson,et al.  Einführung neuer Arzneimittel in europäische Gesundheitssysteme , 2010 .

[17]  H. Eichler,et al.  Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval , 2012, Clinical pharmacology and therapeutics.

[18]  P. Tappenden,et al.  Continuing the multiple sclerosis risk sharing scheme is unjustified , 2010, BMJ : British Medical Journal.

[19]  Peter Littlejohns,et al.  Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research. , 2007, Journal of the Royal Society of Medicine.

[20]  S. Chapman,et al.  Outcomes guarantee for lipid-lowering drugs: results from a novel approach to risk sharing in primary care , 2004 .

[21]  Adrian Towse,et al.  Can’t Get No Satisfaction? Will Pay for Performance Help? , 2012, PharmacoEconomics.

[22]  F. Antoñanzas,et al.  Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach , 2011, Health Economics, Policy and Law.

[23]  J. Vernon,et al.  Pharmaceutical Risk-Sharing Agreements , 2012, PharmacoEconomics.

[24]  Yoav Ben-Shlomo,et al.  Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator , 2009, BMJ : British Medical Journal.

[25]  R. Edlin,et al.  Access with Evidence Development Schemes , 2012, PharmacoEconomics.

[26]  G. Pouvourville.  Risk-sharing agreements for innovative drugs , 2006, The European Journal of Health Economics.

[27]  M. Willis,et al.  A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden , 2010, The European Journal of Health Economics.

[28]  M. Silverstein.  International Journal of Technology Assessment in Health Care (review) , 2015 .

[29]  N. Scolding.  The multiple sclerosis risk sharing scheme , 2010, BMJ : British Medical Journal.

[30]  Anthony O'Hagan,et al.  The Multiple Sclerosis Risk Sharing Scheme Monitoring Study – early results and lessons for the future , 2009, BMC neurology.

[31]  Andrew Briggs,et al.  Access with Evidence Development in the UK , 2012, PharmacoEconomics.

[32]  M. Toumi,et al.  Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts , 2011, BMC health services research.

[33]  C. McCabe,et al.  Funding the Unfundable , 2012, PharmacoEconomics.

[34]  B. Godman,et al.  Current National Initiatives and Policies to Control Drug Costs in Europe: UK Perspective , 2004, The Journal of ambulatory care management.

[35]  Kristen E Downs,et al.  Coverage with Evidence Development: Applications and issues , 2010, International Journal of Technology Assessment in Health Care.

[36]  Alasdair Breckenridge,et al.  Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma , 2008, Nature Reviews Drug Discovery.

[37]  L. Garrison,et al.  Paying for Outcomes: Innovative Coverage and Reimbursement Schemes for Pharmaceuticals , 2009, Journal of managed care pharmacy : JMCP.

[38]  M. Willis,et al.  Reducing uncertainty in value-based pricing using evidence development agreements , 2010, Applied health economics and health policy.

[39]  A. Anell,et al.  Reimbursement and clinical guidance for pharmaceuticals in Sweden , 2005, The European Journal of Health Economics.

[40]  G. Rasi,et al.  Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  R. Weintraub,et al.  Public Funding of Bosentan for the Treatment of Pulmonary Artery Hypertension in Australia , 2012, PharmacoEconomics.

[42]  No cure, no pay , 2005, BMJ : British Medical Journal.

[43]  Louis P Garrison,et al.  Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. , 2010, Health policy.

[44]  J. Espín,et al.  Experiences and Impact of European Risk-Sharing Schemes Focusing on Oncology Medicines , 2011 .

[45]  M. Barry,et al.  Health Technology Assessment International 7th Annual Meeting , 2010, Expert review of pharmacoeconomics & outcomes research.

[46]  R. Lilford.  Response from chair of scientific advisory committee , 2010, BMJ : British Medical Journal.

[47]  U. Tirelli,et al.  Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  Brian Godman,et al.  Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers , 2010, BMC health services research.

[49]  G. Zaric,et al.  The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[50]  E. Lucchi,et al.  Results of a multi-level therapeutic approach for Alzheimer’s disease subjects in the “real world” (CRONOS project): a 36-week follow-up study , 2005, Aging clinical and experimental research.

[51]  J. Lexchin.  Coverage with Evidence Development for Pharmaceuticals: A Policy in Evolution? , 2011, International journal of health services : planning, administration, evaluation.

[52]  Brendan A. Rapple.  Payment by Results , 1994 .

[53]  C. Carbonneil,et al.  A common policy framework for evidence generation on promising health technologies , 2009, International Journal of Technology Assessment in Health Care.

[54]  M. Toumi,et al.  Design of patient access schemes in the UK , 2011, Applied health economics and health policy.